PT - JOURNAL ARTICLE AU - Critelli, Brian AU - Hassan, Amier AU - Lahooti, Ila AU - Noh, Lydia AU - Park, Jun Sung AU - Tong, Kathleen AU - Lahooti, Ali AU - Matzko, Nate AU - Adams, Jan Niklas AU - Liss, Lukas AU - Quion, Justin AU - Restrepo, David AU - Nikahd, Melica AU - Culp, Stacey AU - Lacy-Hulbert, Adam AU - Speake, Cate AU - Buxbaum, James AU - Bischof, Jason AU - Yazici, Cemal AU - Phillips, Anna Evans AU - Terp, Sophie AU - Weissman, Alexandra AU - Conwell, Darwin AU - Hart, Phil AU - Ramsey, Mitch AU - Krishna, Somashekar AU - Han, Samuel AU - Park, Erica AU - Shah, Raj AU - Akshintala, Venkata AU - Windsor, John A AU - Mull, Nikhil K AU - Papachristou, Georgios I AU - Celi, Leo Anthony AU - Lee, Peter J TI - A Systematic Review of Machine Learning-based Prognostic Models for Acute Pancreatitis: Towards Improving Methods and Reporting Quality AID - 10.1101/2024.06.26.24309389 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.26.24309389 4099 - http://medrxiv.org/content/early/2024/06/27/2024.06.26.24309389.short 4100 - http://medrxiv.org/content/early/2024/06/27/2024.06.26.24309389.full AB - Background An accurate prognostic tool is essential to aid clinical decision making (e.g., patient triage) and to advance personalized medicine. However, such prognostic tool is lacking for acute pancreatitis (AP). Increasingly machine learning (ML) techniques are being used to develop high-performing prognostic models in AP. However, methodologic and reporting quality has received little attention. High-quality reporting and study methodology are critical to model validity, reproducibility, and clinical implementation. In collaboration with content experts in ML methodology, we performed a systematic review critically appraising the quality of methodology and reporting of recently published ML AP prognostic models.Methods Using a validated search strategy, we identified ML AP studies from the databases MEDLINE, PubMed, and EMBASE published between January 2021 and December 2023. Eligibility criteria included all retrospective or prospective studies that developed or validated new or existing ML models in patients with AP that predicted an outcome following an episode of AP. Meta-analysis was considered if there was homogeneity in the study design and in the type of outcome predicted. For risk of bias (ROB) assessment, we used the Prediction Model Risk of Bias Assessment Tool (PROBAST). Quality of reporting was assessed using the Transparent Reporting of a Multivariable Prediction Model of Individual Prognosis or Diagnosis – Artificial Intelligence (TRIPOD+AI) statement that defines standards for 27 items that should be reported in publications using ML prognostic models.Results The search strategy identified 6480 publications of which 30 met the eligibility criteria. Studies originated from China (22), U.S (4), and other (4). All 30 studies developed a new ML model and none sought to validate an existing ML model, producing a total of 39 new ML models. AP severity (23/39) or mortality (6/39) were the most common outcomes predicted. The mean area-under-the-curve for all models and endpoints was 0.91 (SD 0.08). The ROB was high for at least one domain in all 39 models, particularly for the analysis domain (37/39 models). Steps were not taken to minimize over-optimistic model performance in 27/39 models. Due to heterogeneity in the study design and in how the outcomes were defined and determined, meta-analysis was not performed.Studies reported on only 15/27 items from TRIPOD+AI standards, with only 7/30 justifying sample size and 13/30 assessing data quality. Other reporting deficiencies included omissions regarding human-AI interaction (28/30), handling low-quality or incomplete data in practice (27/30), sharing analytical codes (25/30), study protocols (25/30) and reporting source data (19/30),.Discussion There are significant deficiencies in the methodology and reporting of recently published ML based prognostic models in AP patients. These undermine the validity, reproducibility and implementation of these prognostic models despite their promise of superior predictive accuracy.Funding noneRegistration Research Registry (reviewregistry1727)Competing Interest StatementNO authors have competing interestsClinical Protocols https://doi.org/10.1186/s41512-024-00169-1 https://pubmed.ncbi.nlm.nih.gov/38561864/ Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yeshttps://figshare.com/s/64a07bd4eb2a0f334e69 DOI: 10.6084/m9.figshare.26078743 https://figshare.com/s/64a07bd4eb2a0f334e69 https://doi.org/10.6084/m9.figshare.26078743